Brokerages Set Alamar Biosciences, Inc. (NASDAQ:ALMR) PT at $30.00

Alamar Biosciences, Inc. (NASDAQ:ALMR) has received an average rating of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $30.00.

Several analysts recently weighed in on ALMR shares. Wall Street Zen raised shares of Alamar Biosciences to a “hold” rating in a report on Saturday, April 25th. Zacks Research upgraded shares of Alamar Biosciences to a “hold” rating in a report on Wednesday, May 13th. Bank of America started coverage on shares of Alamar Biosciences in a research report on Tuesday, May 12th. They issued a “neutral” rating and a $27.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of Alamar Biosciences in a report on Tuesday, May 12th. They issued a “buy” rating and a $28.00 price objective on the stock. Finally, JPMorgan Chase & Co. started coverage on shares of Alamar Biosciences in a research report on Tuesday, May 12th. They set an “overweight” rating and a $30.00 price objective for the company.

Alamar Biosciences Trading Up 1.2%

Shares of NASDAQ ALMR opened at $25.36 on Friday. The business’s 50-day moving average is $23.62. Alamar Biosciences has a 1-year low of $18.84 and a 1-year high of $29.43. The stock has a market cap of $1.76 billion and a P/E ratio of -14.57.

Alamar Biosciences (NASDAQ:ALMR) last announced its quarterly earnings data on Friday, May 8th. The company reported ($1.74) earnings per share (EPS) for the quarter. The firm had revenue of $26.04 million during the quarter.

Alamar Biosciences Company Profile

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.